



Backstep in the right position during injection

## GB INSTRUCTIONS FOR USE FOR BELOTERO® VOLUME LIDOCAINE

### Description

BELOTERO Volume Lidocaine is a sterile, non-pyrogenic, viscoelastic, colourless, transparent cross-linked sodium hyaluronate gel of non-animal origin in a physiological phosphate buffer. BELOTERO Volume Lidocaine contains 0.3 % of lidocaine hydrochloride.

### Presentation

BELOTERO Volume Lidocaine is presented in a single use pre-filled glass syringe, sterilized by moist heat. Each box contains one instruction leaflet, one or several syringe(s), two traceability labels per syringe and sterile CE-marked needle(s) and/or cannula(e) for single use only. The number of syringes, the dimensions and the number of needles and/or cannulae are stated on the external box.

### Composition

Cross-linked sodium hyaluronate:	26,0 mg/ml
Lidocaine hydrochloride:	3,0 mg/ml
Phosphate buffer pH 7 q.s.:	gel volume

Sodium hyaluronate is produced by fermentation of *Streptococcus equi*. The volume of the gel in each syringe is as stated on the external box.

### Indications

BELOTERO Volume Lidocaine is an injectable resorbable implant indicated to restore facial volumes, as for example to enhance the cheeks or the chin. The presence of lidocaine aims to reduce local pain associated with the injection of the gel and to improve patient comfort.

### Posology and administration method

BELOTERO Volume Lidocaine is designed to be injected into the deep subcutaneous layers or above the periosteum by a legally approved practitioner. For successful treatment it is essential that the practitioner has received a specific training on the injection techniques for restoring facial volume. A good knowledge of the anatomy and physiology of the site to be treated is required. The treatment must be carried out under appropriate aseptic conditions. BELOTERO Volume Lidocaine must be injected into a healthy, non-inflamed and previously rigorously disinfected skin. It is recommended to use one of the supplied needles. To ensure optimal use of BELOTERO Volume Lidocaine it is recommended to assemble the needle according to the diagrams above. If the needle becomes obstructed and the injection pressure is too high, stop the injection and change the needle or the cannula. BELOTERO Volume Lidocaine should be injected slowly. The quantity of the gel to be injected depends on the area to be treated and the correction to be achieved. It is recommended not to inject more than 3 ml per treatment site at

each session. Do not over-correct.

Gently massage the treated area after the injection to distribute the product uniformly.

### Contra-indications

BELOTERO Volume Lidocaine is contra-indicated:

- In case of known hypersensitivity to one of the product's components, especially to sodium hyaluronate, lidocaine hydrochloride or to amide-type local anaesthetics,

- In pregnant and breast-feeding women,
- In young patients under 18 years old,
- In patients presenting a general infection.

Do not inject BELOTERO Volume Lidocaine into blood vessels.

Do not inject BELOTERO Volume Lidocaine into the glabellar region.

Do not inject BELOTERO Volume Lidocaine into the tear-trough region.

Do not inject BELOTERO Volume Lidocaine into the lips.

Do not inject BELOTERO Volume Lidocaine into areas presenting cutaneous

problems of an inflammatory or infectious type (acne, herpes...)

Do not inject BELOTERO Volume Lidocaine for correction of superficial wrinkles

and fine lines (injection of the product into the superficial dermis).

Do not inject BELOTERO Volume Lidocaine into an area previously treated with a permanent dermal filler.

### Precautions for use

Before treatment the patient must be informed about the device, its contra-indications and possible side effects.

In the absence of available clinical data on tolerance and efficacy of the injection

of BELOTERO Volume Lidocaine in patients with antecedents or with an active

auto-immune disease or in patients presenting a history of severe multiple

allergies or anaphylactic shock, the practitioner must decide whether to inject

BELOTERO Volume Lidocaine on a case-by-case basis depending on the nature

of the disease as well as the associated treatment. It is recommended to perform

a prior double test to these patients and not to inject if the disease is evolving. It

is also recommended to carefully monitor these patients after injection.

BELOTERO Volume Lidocaine can be used to correct signs of facial fat loss

(lipoatrophy) in patients with human immunodeficiency virus.

It is recommended not to inject BELOTERO Volume Lidocaine in patients with a

history of streptococcal diseases and in patients pre-disposed to hypertrophic

scars or cheloids.

It is recommended not to inject BELOTERO Volume Lidocaine into the periorbital

region.

BELOTERO Volume Lidocaine must not be used in association with other

aesthetic medicine techniques such as peeling, dermabrasion or any type of

laser treatment before complete healing of the last treatment. In any case, even

if the healing occurs earlier, BELOTERO Volume Lidocaine must not be used earlier than 2 weeks after the last treatment. No clinical data is available on the combined use of BELOTERO Volume Lidocaine with the above-mentioned treatments.

No clinical data is available on the injection of BELOTERO Volume Lidocaine into an area already treated with another filling product.

Check the integrity of the inner packaging and the expiry date for both the syringe and the needle prior to use. Do not use these products if the expiry date has lapsed or if the packaging has been opened or damaged.

Patients using antithrombotic substances such as aspirin or non-steroidal anti-inflammatory medications may have increased reactions of haematomas, nodules or bleeding at the injection site.

In cases of patients suffering from epilepsy, impaired cardiac conditions, severely impaired hepatic function or severe renal dysfunction or porphyria, the practitioner must decide whether to inject BELOTERO Volume Lidocaine on a case-by-case basis depending of the nature of the disease as well as the associated treatment.

Practitioners and athletes should consider that lidocaine may produce positive results to anti-doping tests.

It should be noted that the presence of lidocaine may cause local redness or hypersensitivity.

For normal healthy adults, it is recommended that the maximum total dose of lidocaine HCl (without epinephrine) does not exceed 300 mg (or 4.5 mg/kg) per session. Overdosage of lidocaine HCl usually results in sign of the central nervous system or cardiovascular toxicity.

When using concurrently (topical administration...), the total administered dose of lidocaine should be considered. The concomitant use of other local anaesthetic agents or agents structurally related to amide-type local anaesthetics should also be considered since the systemic toxic effects may be additive.

Care should be taken for patients with congenital methemoglobinemia, with glucose-6-phosphate dehydrogenase deficiencies and patients who are receiving concomitant treatment with methemoglobin-inducing agents.

Do not transfer BELOTERO Volume Lidocaine into another container and do not add other substances to the product.

Only the gel is sterile, but not the outside of the syringe.

BELOTERO Volume Lidocaine must not be used with an automated injection system not recommended by MERZ/ANTEIS. If an automatic system is used, it is recommended that the practitioner has previously read its instructions for use and is trained on the use of the system.

Discard the syringe and the remaining product after use.

Do not re-sterilize and do not re-use due to the associated risks including infection.

The patient must avoid applying makeup for at least 12 hours after treatment as well as avoid saunas, Turkish baths and prolonged exposure to the sun or UV rays for 2 weeks after the treatment. Patients should also avoid putting pressure on and/or handling the treated area.

#### Incompatibilities

Sodium hyaluronate precipitates in the presence of quaternary ammonium salts (such as benzalkonium chloride). It is therefore recommended that BELOTERO Volume Lidocaine does not come into contact with such substances.

There is no known interaction with other local or loco-regional anaesthetics.

#### Side effects

Patients must be informed by the practitioner about possible side effects before treatment. A slight bleeding may occur during the injection, and it disappears spontaneously as soon as the injection is finished. In occasional cases one or more of the following may occur either immediately or as a delayed reaction (list not exhaustive):

- Reactions usually associated with injections such as redness, erythema, oedema or pain sometimes accompanied by itching in the treated area. These reactions may last for a week.
- Haematomas in the treated area,
- Swelling in the treated area,
- Indurations or nodules in the treated area,
- Coloration or discoloration in the treated area,
- Allergy to one of the product's components, especially to sodium hyaluronate and lidocaine hydrochloride.
- Cases of necrosis, abscesses and granulomas after sodium hyaluronate injections have been reported in the literature. These rare potential risks must nevertheless be considered.
- Patients should be instructed to report any side effects which last for more than one week to his/her practitioner. The practitioner may then prescribe the patient appropriate treatment.

#### Assembly of needle to syringe

For optimal use of BELOTERO Volume Lidocaine it is important that the needle is properly connected to the syringe. See diagrams 1, 2, 3 and 4.

1. Firmly hold the glass cylinder of the syringe and the Luer-lock adaptor between the thumb and the index fingers.
2. Grasp the protective cap with the other hand and unscrew it.
3. Push & Twist the needle on the syringe until a resistance is felt. Do not over-tight. Over-tightening of the needle may lead to the Luer-lock moving and dislodging from the syringe.
4. Keep holding the Luer-lock and remove the sheath from the needle.

#### Storage

Store between 2 °C and 25 °C. Protect from light and freezing. Avoid mechanical shocks.

#### References

Updated documentation may be available from ANTEIS SA, Switzerland.



Consult instructions for use



Do not use if package is damaged



Single use product. Do not re-use



Open the blister by pulling the Tyvek lid following the arrow



Sterile. Sterilized by moist heat. Only the gel is sterile, but not the outside of the syringe.



Sterile. Sterilized by irradiation. This symbol on the box means only the needle / cannula itself is sterile, but not the outside of the needle / cannula packaging.



Sterile. Sterilized by ethylene oxide. This symbol on the box means only the needle / cannula itself is sterile, but not the outside of the needle / cannula packaging.



Temperature limit of storage: 2 °C – 25 °C



Batch code



Use-by date



CE mark in accordance with Directive 93/42/EEC relating to medical devices. This mark is followed by the notified body number.



Date of manufacture



Manufacturer

Manufacturer of the needles / cannulae is mentioned on the labels of the needles / cannulae and could be:

TSK Laboratory, Japan,  
2-1-5 Hirayanagi-cho, Tochigi-Shi,  
Tochigi-Ken, 328-0012 Japan;

The needles are CE marked

CE 0123

Sterimedix Ltd

1 Madeley Road, North Moors Moat  
Redditch, Worcestershire  
B98 9NB, UK

The cannulae / needles are CE marked

CE 0120

Manufacturer of BELOTERO Volume Lidocaine:

ANTEIS SA  
18 Chemin des Aulx  
CH-1228 Plan-les-Ouates  
Geneva, Switzerland

Australian Sponsor Name and Address:

Merz Australia Pty Ltd  
Level 3, 244 Coward Street  
Mascot, NSW, 2020  
Australia



Caution